Topics

Ankylosing Spondylitis

TNFi Effectively Decreases Radiographic Progression in Early Ankylosing Spondylitis

TNFi Effectively Decreases Radiographic Progression in Early Ankylosing Spondylitis

Effective suppression of inflammation with tumor necrosis factor inhibitor therapy decreases radiographic progression in early ankylosing spondylitis.

Rates of Knee, Hip Arthroplasty Increasing Among Patients With Ankylosing Spondylitis

Researchers observed increased rates of both knee and hip arthroplasties in older patients with ankylosing spondylitis.

Lower Cardiorespiratory Fitness Associated With Increased CVD Risk in Ankylosing Spondylitis

Reduced cardiorespiratory fitness may be associated with increased risk for CVD in ankylosing spondylitis.

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

Treatment with risankizumab was not effective in reducing the signs and symptoms of ankylosing spondylitis at 12 weeks.

Ankylosing Spondylitis Linked to Increased Prevalence of Left Ventricular Hypertrophy

Data strengthen the indication for performing a thorough CVD risk assessment in patients with inflammatory disorders.

Fatigue Affects Work Disability in Rheumatoid Arthritis, Ankylosing Spondylitis

Fatigue had a significant and independent effect on work disability measures in rheumatoid arthritis and ankylosing spondylitis.

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

It is unclear whether ankylosing spondylitis and axial psoriatic arthritis are part of a spectrum of the same disease, or whether they are separate diseases with overlapping features.

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

Researchers used data from social media to identify concerns and perceptions regarding biologic therapies.

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

Researchers assessed achievement of minimally important changes in SPARCC scores in biologic-naive patients with ankylosing spondylitis treated with tofacitinib or placebo.

Sign Up for Free e-newsletters